Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme. by Hanson, Joseph A et al.
UC Office of the President
Recent Work
Title
Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.
Permalink
https://escholarship.org/uc/item/9db4b7s8
Journal
The Permanente journal, 17(4)
ISSN
1552-5767
Authors
Hanson, Joseph A
Hsu, Frank PK
Jacob, Arun T
et al.
Publication Date
2013
DOI
10.7812/TPP/13-081
License
https://creativecommons.org/licenses/by/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
68 The Permanente Journal/ Fall 2013/ Volume 17 No. 4
REVIEW ARTICLE
Antivascular	Endothelial	Growth	Factor	Antibody		
for	Treatment	of	Glioblastoma	Multiforme
Joseph A Hanson; Frank P K Hsu, MD, PhD; Arun T Jacob, MD; Daniela A Bota, MD, PhD; Daniela Alexandru, MD Perm J 2013 Fall;17(4):68-74
http://dx.doi.org/10.7812/TPP/13-081
Joseph A Hanson is a Medical Student in the Departments of Neurology and Neurosurgery at the University of California 
Irvine in the City of Orange. E-mail: jhanson1@uci.edu. Frank P K Hsu, MD, PhD, is a Professor in the Department of 
Neurosurgery at the University of California Irvine in the City of Orange. E-mail: fpkhsu@uci.edu. Arun T Jacob, MD, is a 
Neurosurgeon in the Department of Neurosurgery at Baptist Memorial Healthcare in Memphis, TN. E-mail:aruntjacob@gmail.com. 
Daniela A Bota, MD, PhD, is an Assistant Professor in the Department of Neurology at the University of California Irvine in 
the City of Orange. E-mail:dbota@uci.edu. Daniela Alexandru, MD, is a Neurosurgeon at the University of California Irvine 
Medical Center in Orange. E-mail: danielaa@uci.edu.
Introduction
Glioblastoma multiforme (GBM) is 
a highly aggressive tumor with a rapid 
progression and poor prognosis. This 
tumor comprises nearly 50% of gliomas 
and 25% of all primary brain tumors.1-3 
According to the most recent report from 
the Central Brain Tumor Registry of the 
United States, there are approximately 
10,000 new cases of GBM recorded annu-
ally in the US.3 The development of GBM 
is positively correlated with age, reaching 
a peak in gross incidence at 45 to 64 years4 
and highest per capita incidence at ages 
74 to 85 years.3
Unfortunately, GBM is the most deadly 
form of glioma, classified as Stage 4 
infiltrative glioma by the World Health 
Organization.5 The median overall survival 
is poor, ranging from 9 to 19 months in 
maximally treated patients,6,7 and the 
1-year survival rate has been recorded at 
approximately 32%.2 Survival rates have 
historically increased with the advent 
of new surgical techniques and chemo-
therapeutic options,2 and they continue 
to slowly rise.4 GBM, however, recurs 
almost universally regardless of treatment 
regimen. 
The extent of surgical resection is an 
independent risk factor for survival, with 
gross total resection increasing survival.6,8,9 
However, even those patients with ra-
diographically demonstrated resection in 
excess of 98% tumor volume experience 
nearly 100% recurrence, presumably 
because of the persistence of quiescent 
glioblastoma tumorigenic stem cells.8,10
Standard therapy for GBM involves 
surgical resection to the maximal extent 
possible with adjuvant radiotherapy and 
chemotherapy. Initial studies examined 
nitrosourea-based compounds to target 
GBM because of their lipophilicity and 
ability to cross the blood-brain barrier. 
Large meta-analyses have revealed that 
lomustine and carmustine in combination 
with whole-brain radiation or stereotactic 
radiotherapy yielded only modest results, 
with 1-year survival up to 35%, a 6% 
increase compared with radiotherapy 
alone.11 Phase 2 trials for combinations of 
carboplatin, procarbazine, and fluoroura-
cil were similarly unimpressive, reaching a 
1-year survival proportion of 32%.12
Temozolomide (Temodar, Schering-
Plough Corp, Kenilworth, NJ) is an al-
kylating agent approved by the US Food 
and Drug Administration (FDA) for use in 
newly diagnosed GBM,13 which has been 
successfully used in the treatment of GBM. 
The Stupp protocol demonstrated increased 
survival of 2.5 months (12.2 months to 14.6 
months) with the addition of temozolomide 
at dosages of 75 mg/m2/day for 7 days 
during radiotherapy and not exceeding 49 
days.7,14,15 Following a 4-week break in ther-
apy, temozolomide was administered again 
for 5 days in 28-day cycles for between 
1 and 6 cycles. The study demonstrated 
a survival benefit at 2 years of 27.2% for 
patients receiving adjuvant temozolomide 
after maximal surgical resection, up from 
10.9% in patients with adjuvant radiotherapy 
alone.7 The survival benefit at 5 years was 
9.8% for patients with combination therapy 
compared with 1.9% for patients who re-
ceived radiation therapy alone.7,14,15
With the advent of temozolomide for 
the treatment of GBM, a new gene prod-
uct was identified that conferred survival 
advantage. Expression of O6-methylgua-
nine-DNA methyltransferase (MGMT), an 
enzyme involved in DNA repair, was linked 
to shorter survival.16 The epigenetic silenc-
ing of the MGMT expression by methyla-
tion of the promoter was linked with a 
survival advantage in patients receiving 
temozolomide, with an overall survival 
of 18.2 months in patients with MGMT 
methylation compared with 12.2 months 
in patients without MGMT methylation.16
Abstract
Despite	aggressive	investigation,	glioblastoma	multiforme	(GBM)	remains	one	of	the	dead-
liest	cancers,	with	low	progression-free	survival	and	high	one-year	mortality.	Current	first-line	
therapy	includes	surgery	with	adjuvant	radiation	therapy	and	cytotoxic	chemotherapy,	but	
virtually	all	tumors	recur.	Given	the	highly	vascular	nature	of	GBM	and	its	high	expression	
of	vascular	endothelial	growth	factor	and	other	angiogenic	factors,	recent	investigation	has	
turned	to	bevacizumab,	an	antivascular	endothelial	growth	factor	monoclonal	antibody,	
for	treatment	of	recurrent	GBM.	Phase	2	studies	demonstrated	the	efficacy	and	safety	of	
bevacizumab	therapy	for	recurrent	GBM,	which	led	to	its	approval	by	the	US	Food	and	Drug	
Administration	in	2009	for	use	in	recurrent	GBM.	Since	then,	several	new	Phase	2	studies	
and	retrospective	series	have	demonstrated	that	bevacizumab	significantly	increased	six-
month	progression-free	survival	in	patients	with	recurrent	GBM	and	may	do	so	in	new-onset	
GBM.	The	objective	of	this	review	is	to	provide	a	collective	resource	for	these	materials,	
highlighting	the	efficacy	and	safety	of	bevacizumab	and	calling	for	increased	investigation	
toward	its	optimal	application	in	the	management	of	high-grade	glioma.
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Despite chemotherapy and radiation, 
GBM universally recurs, and at recurrence 
the disease rapidly becomes lethal.12 Some 
of the treatments considered at recur-
rence were repeated surgery, repeated 
irradiation, or other chemotherapies,17,18 
which all have yielded less than modest 
results. Because of the altered signal-
ing pathways and frequent mutations 
found in GBM, the focus of therapy has 
shifted toward the use of biologics and 
target-specific molecular drugs for treat-
ment.18 Bevacizumab (Avastin, Genentech, 
South San Francisco, CA) is a human-
ized antivascular endothelial growth 
factor (anti-VEGF) immunoglobulin G1 
monoclonal antibody that was granted 
accelerated FDA approval in 2009 as a 
single-agent therapy for use in recurrent 
GBM refractory to prior chemotherapy 
or radiotherapy (Figure 1).19 This review 
will evaluate the theoretical mechanism 
of bevacizumab and its use and efficacy 
in treating glioma, to demonstrate the 
benefits it yields for well-selected patients 
with newly diagnosed or recurrent GBM.
Angiogenesis, Vascular 
Endothelial Growth Factor, 
and Glioblastoma
Angiogenesis, the process of creating 
new blood vessels and vascular branches 
from preexisting tissues, is a vital compo-
nent of tumorigenesis; it is required for 
solid tumor growth beyond a 0.125-mm 
radius because of limitations in nutrient 
and oxygen diffusion capacity.20 This 
process requires an abundance of unique 
growth factors and cell adhesion mol-
ecules, which include different isoforms 
of VEGF (VEGF-A, VEGF-B, VEGF-C, 
and VEGF-D) as well as platelet-derived 
growth factor.21 A receptor tyrosine kinase 
ligand, VEGF-A has been identified as a 
key promotor of tumor angiogenesis.22 In 
tumor microenvironments such as GBM, 
VEGF secretion is increased to promote 
abnormal angiogenesis.23 In GBM, the 
highest concentrations of VEGF are 
found in areas of necrosis and hypoxia 
in the tumor, because VEGF production 
is stimulated in tumorigenic glial cells by 
hypoxia and the concomitant upregula-
tion of hypoxia inducible factor-1.24 The 
resultant vasculature is often abnormal, 
creating the potential for the development 
of new areas of necrosis and hypoxia, thus 
Table 1. Bevacizumab for recurrent glioblastoma multiforme
 
Author
 
Trial
Combination  
therapy
 
Use
 
Number
Median age, 
years (range)
 
KPS
6-month PFS 
(95% CI)
Median  
PFS
Median  
OS
Friedman,32 
2009
Phase 2 Irinotecan Adjuvant, 
recurrence
85 54  
(23-78)
> 70 42.6%  
(29.6%-55.5%)
4.2 months 9.2 months
None Adjuvant, 
recurrence
82 57  
(23-79)
> 70 50.3%  
(36.8%-63.9%)
5.6 months 8.7 months
Vredenburgh,34 
2007
Phase 2 Irinotecan Adjuvant, 
recurrence
35 48  
(18-66)
3%  
< 70
46%  
(32%-66%)
24 weeks 42 weeks
Vredenburgh,47 
2012
Phase 2 Radiotherapy, 
temozolomide
Adjuvant 125 56.2  
(19-80)
> 70 — 13.8 months —
Norden,36 
2009
Phase 2 Irinotecan Adjuvant, 
recurrence
34 54.5  
(31-74)
> 70 40.0% 21.9 weeks 37.4 weeks
Bokstein,35 
2007
Phase 2 Irinotecan Adjuvant, 
recurrence
17 56  
(38-74)
> 50 25.0% 4.2 months 7 months
Kreisl,39 
2009
Phase 2 None; irinotecan on 
disease progression
Adjuvant, 
recurrence
48 53  
(21-69)
> 60 29%  
(18%-48%)
16 weeks 31 weeks
Lai,45 
2011
Phase 2 Radiotherapy, 
temozolomide
Adjuvant 70 57.4  
(31.3-75.8)
> 60 — 13.6 months 19.6 months
Cohen,19 
2009
Phase 2 Irinotecan Adjuvant, 
recurrence
85 54  
(23-78)
> 70 36.0%  
(25.0%-47.0%)
4.2 months —
Irinotecan Adjuvant, 
recurrence
56 54  
(21-69)
> 70 — 3.9 months —
Ali,37 
2008
Case series Irinotecan Adjuvant, 
recurrence
13 53  
(32-76)
— — 24 weeks 27 weeks
Hasselbalch,33 
2010
Phase 2 Irinotecan, cetuximab Adjuvant, 
recurrence
43 54  
(23-70)
— 33%  
(19%-48%)
16 weeks 30 weeks
Nghiemphu,50 
2009
Retrospective None; irinotecan Adjuvant, 
recurrence
44 — — — 4.25 months 9.0 months
Gutin,41 
2009
Phase 2 Hypofractionated 
stereotactic radiotherapy
Adjuvant, 
recurrence
20 56 — 65.0% — 12.5 months
Chamberlain,40 
2010
Retrospective None Adjuvant, 
recurrence
50 64  
(36-70)
> 60 42.0% 1 month 8.5 months
Gilbert,38 
2009
Phase 2 Irinotecan Adjuvant, 
recurrence
57 57 Median: 
80
37%  
(24-50%)
— —
Sathornsumetee,42 
2010
Phase 2 Erlotinib Adjuvant, 
recurrence
25 52.4  
(24.1-70.4)
> 70 29.2%  
(13.0%-47.6%)
18 weeks 44.6 weeks
CI = confidence interval; KPS = Karnofsky performance score; OS = overall survival; PFS = progression-free survival; (—) = none described.
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continuing the cycle.24 Both the density 
of the microvasculature and the level of 
VEGF secretion in glial tumors have been 
associated with tumor grade and clinical 
outcomes, with low overall survival scores 
for patients who expressed high levels of 
messenger RNA secretion.18,25-27 Therefore, 
the development of an antiangiogenic 
biologic therapy targeting VEGF-A for 
highly vascular tumors such as glioblas-
toma gained popularity.28 It is postulated 
that anti-VEGF-A immunoglobulin G 
acts by sequestering VEGF and therefore 
preventing the protein from initiating 
the signaling cascade, which will lead 
to recruitment of endothelial cells and 
proliferation of blood vessels (Figure 2). 
In glioma models the preclinical data 
for the use of bevacizumab showed that 
the tumors exhibited microvascular re-
gression, normalization of mature blood 
vessels, and inhibition of new vessel 
growth.29 Clinical trials demonstrated 
efficacy of bevacizumab and led to FDA 
approval for use in malignant colorectal 
cancer in 2004 and recurrent glioblastoma 
in 2009.22 Two independent, randomized, 
prospective trials of bevacizumab for 
recurrent GBM demonstrated an increase 
in progression-free survival (PFS) of 3.9 
to 4.2 months in patients with recurrent 
disease already treated with prior surgery, 
radiotherapy, and temozolomide.19 Beva-
cizumab received accelerated approval as 
single-agent therapy for recurrent GBM 
refractory to surgical treatment, chemo-
therapy, and radiotherapy.19
Bevacizumab Use in 
Glioblastoma
Most investigations into bevacizumab 
therapy for GBM have consisted of Phase 
2 trials to determine safety and efficacy 
of the biologic agent in patients who 
have recurrence of GBM after attempting 
first-line surgical resection followed by 
adjuvant radiotherapy and temozolomide 
chemotherapy. The primary endpoint 
for these studies was 6-month PFS30; the 
North American Brain Tumor Consortium 
uses 6-month PFS as the efficacy endpoint 
of therapeutic trials for adult patients with 
recurrent high-grade gliomas.31 Historic 
evidence suggests that 6-month PFS in 
absence of treatment of recurrent GBM 
ranges from 9%30 to 16%.31 These find-
ings are based on retrospective data from 
pooled trials of nonefficacious therapies; 
most investigators usually tailor their stud-
ies to demonstrate the presence or lack of 
a significant difference from this baseline.
Patient populations are typically se-
lected on the basis of performance status, 
failure of first-line therapy with radiologic 
proof of disease progression, and lack of 
major comorbidities in light of a histologic 
diagnosis of Grade 4 glioma. Exclusion 
criteria generally include previous treat-
ment with carmustine wafer or anti-VEGF 
agents; history of bleeding diathesis, 
intracranial hemorrhage, or coagulopa-
thy; clinically significant cardiovascular 
disease; recent arterial thromboembolism; 
uncontrolled hypertension; and Karnofsky 
performance score less than 70.19,32,33
Efficacy
In the first prospective Phase 2 trial 
of bevacizumab, Vredenburgh et al34 
administered irinotecan, a topoisomerase 
inhibitor, as conjunctive adjuvant therapy 
because of the combination’s history of 
success in colorectal cancer. They ob-
served partial or complete response in 20 
(57%) of 35 patients, with a 6-month PFS 
rate of 46% (n = 16; 95% confidence inter-
val [CI], 32%-66%),34 in excess of the base-
line 6-month PFS rate of 9% to 16% in 345 
untreated patients with recurrent GBM.30,31 
A study sponsored by Genentech demon-
strated similar findings, noting a 6-month 
PFS rate of 36.0% (n = 31; CI, 25.0%-
47.0%) in a Phase 2 trial of bevacizumab 
and irinotecan in 85 patients.19 Since that 
time, multiple authors have documented 
6-month PFS rates for bevacizumab and 
irinotecan combination therapy between 
25% and 40% (Table 1).35-38 Friedman et 
al32 performed a large trial both with and 
without combination irinotecan therapy. 
They found a 6-month PFS rate of 42.6% 
(CI, 29.6%-55.5%) in patients receiving 
combination irinotecan-bevacizumab 
therapy and a 6-month PFS rate of 50.3% 
(CI, 36.8%-63.9%) in those receiving 
single-agent bevacizumab, with no signifi-
cant difference in 6-month PFS or median 
PFS between the 2 arms. Investigation into 
bevacizumab monotherapy has yielded 
similar results. Kreisl et al39 recorded a 
6-month PFS rate of 29% (n = 14; CI, 
18%-48%) in a Phase 2 trial of 48 patients, 
and Chamberlain and Johnston40 found 
a 6-month PFS rate of 42% (n = 21) in a 
retrospective review of 50 patients using 
bevacizumab monotherapy. Overall, the 
results between single-agent bevacizumab 
and combination therapy with cytotoxic 
agents, specifically irinotecan, have been 
similar to date, with no clear superiority 
among either regimen.
New combination therapies are cur-
rently under clinical investigation as well. 
Hasselbalch et al33 combined adjuvant 
bevacizumab therapy with irinotecan and 
cetuximab, a monoclonal anti-epidermal 
growth factor antibody also used in 
colorectal cancer, and reported a 6-month 
PFS of 33% (n = 14; CI 19%-48%) among 
43 patients. Gutin et al41 administered hy-
pofractionated stereotactic radiotherapy in 
combination with bevacizumab for treat-
ment of recurrent GBM in 20 patients and 
reported a 65% (n = 13; CI unreported) 
6-month PFS. Additionally, Sathornsume-
tee et al42 combined bevacizumab with 
erlotinib, an epidermal growth factor 
receptor tyrosine kinase inhibitor, in 25 
patients with recurrent GBM and found a 
6-month PFS rate of 29.2% (n = 7).
These studies are noncomparative, 
Phase 2 safety studies, and there is no sta-
tistically significant evidence to indicate the 
comparative effectiveness of bevacizumab 
in single-agent or combination therapy for 
recurrent GBM. However, all studies in our 
literature search, regardless of combination 
therapy, reported 6-month PFS rates in ex-
cess of 25% (Table 1), suggesting that there 
may be benefit to bevacizumab therapy in 
delaying disease progression.Figure 1. Treatment algorithm for glioblastoma 
multiforme (GBM).
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Safety
Bevacizumab is typically well tolerated 
by patients, and its side effect profile 
in those with GBM is equivalent to the 
adverse events encountered in patients 
receiving bevacizumab therapy for malig-
nant colorectal cancer, non-small-cell lung 
cancer, and metastatic breast cancer.43 In 
trials of bevacizumab for recurrent GBM, 
the most commonly encountered Grade 
3 or 4 adverse events (graded according 
to the National Cancer Institute Common 
Terminology Criteria for Adverse Events, 
version 3.0)44 include hypertension, 
hemorrhage (eg, epistaxis, intracranial), 
thromboembolic complications, and 
convulsions.32 Other serious adverse 
events reported in the literature include 
proteinuria, gastrointestinal tract perfo-
ration, wound healing complications, 
reversible posterior leukoencephalopathic 
syndrome, intractable convulsion, and 
neutropenia,32 but the frequency of such 
outcomes is generally very low (< 4% in 
large studies).19,32
The overall rate of Grade 3 or greater 
adverse events in studies of bevacizumab 
to date has ranged from 12% to 66%32,35 
(Table 2). These events are hypothesized 
to be caused by the incidental effect of 
anti-VEGF blockade on the vasculature 
of normal healthy tissues or caused by 
postoperative wound healing complica-
tions presumably caused by inhibition 
of neovascularization of wound tissue in 
neurosurgical patients.18 Although there 
are no formal recommendations for the 
interval between surgery and initiation 
of bevacizumab therapy in patients after 
repeated surgical resection of GBM, most 
Table 2. Adverse outcomes in bevacizumab trials
 
Author
Combination  
therapy
Grade ≥ 3 adverse 
events, percentage
Grade 5 adverse 
events, percentage
Description of Grade 5  
adverse events
Friedman,32 2009 Irinotecan 65.8 1.3 Convulsion
None 46.4 2.5 Neutropenia/infection, pulmonary embolism
Vredenburgh,34 2007 Irinotecan 22.9 0.0 —
Bokstein,35 2007 Irinotecan 11.8 0.0 —
Kreisl,39 2009 None 27.1 0.0 —
Cohen,19 2009 Irinotecan 46.4 3.6 Neutropenia/infection, pulmonary embolism, 
operative complications
Ali,37 2008 Irinotecan 23.1 0.0 —
Hasselbalch,33 2010 Irinotecan, cetuximab 58.0 0.0 —
Chamberlain,40 2010 None 24.0 0.0 —
Gilbert,38 2009 Irinotecan 49.0 2.0 Intracranial hemorrhage
(—) = none described.
Figure 2. Artist’s depiction of mechanism of action of bevacizumab. Tumor secretes 
vascular endothelial growth factor (VEGF) to promote proliferation of blood vessels 
(top). Bevacizumab sequesters VEGF, leading to decreased vascular proliferation and 
decreased tumor size (bottom).
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studies in the literature cite 3 to 4 weeks 
as an appropriately safe interval.41,45 
Neurosurgeons and neuro-oncologists 
should be wary of the potential for ad-
verse outcomes with premature repeated 
operation in patients using bevacizumab 
who require additional resection of tumor 
after initiation of adjuvant chemotherapy.
Grade 5 events (ie, those 
leading to death) are rare, 
occurring in less than 3.6% 
of patients (Table 2). Causes 
of mortality in clinical stud-
ies thus far include infection 
secondary to drug-induced 
neutropenia, pulmonary em-
bolism, and intracranial hemor-
rhage.19,32,38 Even in studies in 
which fatal intracranial hemor-
rhage occurred,38 the rate of 
hemorrhage approaches the 
expected incidence of intra-
cranial hemorrhage in patients 
with intracranial malignancy in 
the absence of treatment (ap-
proximately 2.5%).46
There is some evidence that 
single-agent bevacizumab is 
associated with lower rates 
of Grade 3 or higher adverse 
events than combination therapy with 
irinotecan.18,38,40 Chamberlain et al40 and 
Kreisl et al38 noted Grade 3 or greater 
adverse events in only 24.0% to 27.1% of 
enrolled patients receiving single-agent 
bevacizumab therapy, whereas bench-
mark studies for combined bevacizumab 
and irinotecan treatment, such as by 
Friedman et al,32 found rates of Grade 
3 or greater adverse events as high as 
65.8%. Regardless, these data are limited 
to cross-trial comparisons of different 
study populations. Friedman and col-
leagues’ own single-agent bevacizumab 
arm had Grade 3 or greater adverse events 
in 46.4% of patients, and any differences 
in the safety profile of single-agent or 
combined therapies of bevacizumab are 
still speculative at this time.
Prospects for Future Use
More recent investigations have led 
to the experimental use of bevacizumab 
as combination therapy with first-line 
adjuvant radiotherapy and temozolomide 
after surgical resection of new-onset 
GBM. Vredenburgh et al47 treated 125 
patients with bevacizumab, radiotherapy, 
and temozolomide beginning 4 weeks 
after surgical resection and found no 
increase in patient dropout compared 
with similar trials of radiotherapy and 
temozolomide in the absence of bevaci-
zumab. They found that 93% of patients 
were able to tolerate combined adjuvant 
therapy of irradiation, temozolomide, 
and bevacizumab compared with an 
83% completion rate in similar trials of 
temozolomide and irradiation alone.47 
Importantly, less than 2% of patients 
enrolled experienced clinically significant 
intracranial hemorrhage or craniotomy 
wound dehiscence despite theoretical 
concerns of increased risks of wound 
healing complications.47 Furthermore, 
the median PFS was measured at 13.8 
months, which compared favorably with 
the median PFS of 6.9 months in similar 
temozolomide and radiotherapy trials.14
Lai et al45 also treated 70 patients with 
adjuvant bevacizumab, temozolomide, 
and radiotherapy in new-onset GBM 
and recorded a statistically significant 
increase in 6-month PFS (range, 7.6 
months to 13.6 months) without change 
in median overall survival compared 
with accumulated data of radiotherapy 
plus temozolomide without bevacizumab 
given at their institution.
These were noncomparative trials 
to determine the efficacy and safety of 
bevacizumab in combination with radio-
therapy and temozolomide. Bevacizumab 
is currently labeled for use only in patients 
with recurrent GBM with progression 
after the options of surgical resection, 
radiotherapy, and temozolomide che-
motherapy have been exhausted. Phase 
2 studies of temozolomide have shown 
a 6-month PFS of 13% to 29% (95% CI) 
in temozolomide-treated patients48; these 
studies suggest that bevacizumab may 
provide clinical benefit above this bench-
mark. The potential safety of bevacizumab 
after a sufficient postoperative interval is 
theorized to increase the clinical benefit 
of angiogenic inhibition and to improve 
the clinical effect of bevacizumab.47
Discussion
Glioblastoma multiforme is a highly 
aggressive and deadly class of malig-
nancy. Patients receiving this diagnosis 
have on average less than a year to live, 
and even those who respond to first-line 
therapy will likely face most of that time 
neurologically impaired or debilitated. 
Furthermore, the financial expense of 
bevacizumab is daunting. One study 
estimated the cost per quality-adjusted 
life year for use in colorectal and breast 
cancer at approximately $300,000.49 Even 
for these neurologically intact patients, 
only 25% of surveyed oncologists believed 
that bevacizumab offered “good value.”49 
However, most surveyed oncologists 
believe that patients should have access 
to high-quality care despite the financial 
costs of treatment, as it is difficult to place 
a price tag on extending life.49
Options for patients with GBM are 
limited at tumor recurrence. Often, re-
peated irradiation and repeated surgery 
are not suitable options, and the tumors 
have already demonstrated resistance 
to first-line cytotoxic alkylating therapy 
with temozolomide.18 Despite the data 
supporting the safety and efficacy of 
bevacizumab (measured by increased 
6-month PFS) in patients with recurrent 
GBM (Tables 1 and 2), some studies 
show only a very modest increase in 
median overall survival.36 Lai et al,45 in 
their study of bevacizumab in combi-
nation with adjuvant radiotherapy and 
temozolomide in new-onset GBM, also 
found a statistically significant difference 
in 6-month PFS among patients receiv-
ing bevacizumab compared with historic 
institutional data without corresponding 
change in median overall survival. This 
suggests that the use of bevacizumab 
delays progression. Although it has little 
effect on overall survival, bevacizumab 
therapy maintains the patient’s Karnof-
sky performance score by increasing 
the PFS and consequently increasing 
the quality of life. 
However, there exist no reliable a priori 
evaluations to determine whether a pa-
tient is suitable for bevacizumab therapy, 
or in which patients bevacizumab will 
provide optimal benefit.18 Increased age 
(> 55 years) and lower performance (Kar-
nofsky performance score < 80) has been 
associated with greater benefit from beva-
cizumab, possibly because of the higher 
VEGF expression in these patients.50 
Furthermore, patients treated with beva-
cizumab are able to maintain functional 
status longer than patients historically not 
Although 
it has little 
effect on 
overall 
survival, 
bevacizumab 
therapy 
maintains 
the patient’s 
Karnofsky 
performance 
score by 
increasing 
the PFS and 
consequently 
increasing the 
quality of life.
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treated with bevacizumab.50 Age at time of 
diagnosis is still the strongest prognostic 
indicator for survival in GBM, with median 
survival as low as 2 months in patients 
older than age 80 years.51 Although over-
all survival for patients with GBM has 
increased since the 1990s, the youngest 
(aged 20 to 44 years) and most functional 
patients have received the greatest benefit, 
achieving 2-year survival rates as high as 
39%; the most elderly patients (aged > 80 
years) have experienced minimal benefit 
and have achieved a disappointing 2-year 
survival rate of 1%.4
Recent studies of bevacizumab threaten 
to change this trend by increasing the 
median PFS and prolonging the func-
tional status of patients whose disease 
was previously resistant to traditional 
radiotherapy and cytotoxic adjuvant 
therapies. Furthermore, recent studies 
have begun experimental investigation 
into the use of bevacizumab as adjuvant 
therapy for new-onset GBM.45,47 Given 
the antiangiogenic mechanism of be-
vacizumab, it is widely theorized that 
early administration of VEGF inhibitors 
will prevent wound healing and increase 
operative complications.52 These stud-
ies suggest not only that postoperative 
administration of bevacizumab (after an 
appropriate time window) is safe, it may 
actually be efficacious in prolonging me-
dian PFS and increasing six-month PFS.45,47 
Preliminary results from the AVAglio study, 
the first prospective Phase 3 trial for the 
use of bevacizumab (Avastin) in recurrent 
glioma, were recently announced at the 
2013 American Society of Clinical Oncol-
ogy meeting. The study found that the 
addition of bevacizumab to treatment of 
newly diagnosed GBM did not improve 
overall survival, although it did improve 
the PFS but not to a significant statistical 
criterion.53 The study also found that the 
MGMT methylation profile did not identify 
to be a selective benefit, but instead was 
a risk subset. To date, the results of this 
study suggest that bevacizumab should 
not be used as first-line therapy for the 
treatment of GBM.
Bevacizumab has been shown to be 
safe in new-onset and recurrent disease. 
This is especially important for older 
patients (age > 55 years) for whom the 
prognosis is worse and the benefits of 
bevacizumab more promising. More pro-
spective Phase 3 trials are needed to de-
termine the appropriate patient population 
for bevacizumab therapy, the appropriate 
combination therapy, and the appropriate 
timing of therapy (adjuvant for new-onset 
vs recurrent disease). Although the effect 
on overall survival and the appropriate 
patient population is still unclear for beva-
cizumab, its ability to increase the number 
of patients who survive for 6 months 
without impairment should be cause for 
further investigation and clinical use. v
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Mystery
As	long	as	our	brain	is	a	mystery,	the	universe,		
the	reflection	of	the	structure	of	the	brain,	will	also	be	a	mystery.
—	Santiago	Ramón	y	Cajal,	1852-1934,	Spanish	pathologist,	histologist,	neuroscientist,		
and	1906	Nobel	Laureate	for	Physiology	or	Medicine
